Developed using technology from partner Seattle Genetics, the drug is a monoclonal antibody containing a toxic chemotherapy that attacks cancer cells if they express glycoprotein NMB, or GPNMB.
FORBES: Celldex Therapeutics Breast Cancer Drug Shows Strong Results In Some Patients